So what To Expect From the Rapamycin?

Primary endpoint was investigator-assessed progression-free survival (PFS). Results: Median age, CIRS score, and CrCl at baseline were 73 y, 8, and 61.1?mL/min for stage 1a (Clb vs GClb, 356 pts) and 73 y, 8, and 62.1?mL/min for stage 1b (Clb vs RClb, 351 pts, triggered by a different event rate). Key efficacy and safety results are below: Abstract 056 Table 1. Total stage 1 N?=?589 Stage 1a Stage 1b Clb GClb Clb RClb N?=?118 N?=?238 N?=?118 N?=?233 * still immature, http://www.selleckchem.com/products/Rapamycin.html treament options in this population. GClb vs RClb will be compared in stage 2 analysis with more follow-up available. 057 UPDATED RESULTS OF A PHASE I FIRST-IN-HUMAN STUDY OF THE BCL-2 INHIBITOR ABT-199 (GDC-0199) IN PATIENTS WITH RELAPSED/ REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKAEMIA http://www.selleck.cn/products/AP24534.html (CLL) J. Seymour,1 M. Davids,2 J. Pagel,3 B. Kahl,4 W. Wierda,5 T. Miller,6 J. Gerecitano,7 T. Kipps,8 M. Anderson,9 D. Huang,9 D. Darden,10 L. Gressick,10 C. Nolan,10 J. Yang,10 T. Busman,10 A. Graham,10 E. Cerri,10 S. Enschede,10 R. Hummerickhouse,10 A. Roberts.9 1Haematology, Peter MacCallum Cancer Centre, Melbourne, Australia; 2Hematology, Dana-Farber Cancer Institute, Boston, USA; 3Oncology, University of Washington, Seattle, USA; 4Medicine, University of Wisconsin, Madison, USA; 5Oncology, University of Texas, Houston, USA; 6Medicine, University of Arizona, Tucson, USA; 7Oncology, Memorial Sloan-Kettering Cancer Center, New York, USA; 8Hematology/Oncology, University of California San Diego, San Diego, USA; 9Haematology, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia; 10Oncology, AbbVie, http://www.selleckchem.com/products/jq1.html North Chicago, USA. Background: Targeting BCL-2 is a promising strategy for treating chronic lymphocytic leukaemia (CLL), including disease refractory to fludarabine (F), or with del(17p). ABT-199 is a selective BCL-2 inhibitor with >500-fold higher affinity for BCL-2 (Ki